Johnson & Johnson is investing more than $55 billion in the U.S. over the next four years in manufacturing, research and development, and technology. This represents a 25% increase in investment compared to the previous four years and builds on the company’s U.S. investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act.

“This announcement accelerates our nearly 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Our increased U.S. investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but manufacture cutting edge medicines to treat patients in America and around the world.”

The investment aims to support American innovation and manufacturing. In addition to the facility in Wilson, NC, the increased investment in the U.S. over the next four years includes:

Three new advanced manufacturing facilities and the expansion of several existing sites across the Company’s Innovative Medicine and MedTech businesses that will create high-paying, high-technology jobs. 

Significant investments in extensive R&D infrastructure aimed at developing innovative treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.

Increased technology investments to help make drug discovery and development faster, support workforce training and enhance business operations.

The North Carolina investment creates jobs in Wilson, NC, where the J&J officially broke ground on its new, 500,000 sq.-ft., state-of-the-art biologics manufacturing facility.

The North Carolina facility will expand capacity to manufacture next-gen medicines for cancer, immune-mediated and neurological diseases, and will support approximately 5,000 jobs during construction and create over 500 positions in NC.

J&J aims to create a $3 billion impact across the state in the first 10 years of operations.

Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country and is a leading investor in American innovation and R&D. With a focus on pharmaceuticals and medical technology, J&J covers the full spectrum of disease, from cardiology to cancer, mental health to vision, cell therapies to robotics.